Nanomaterial-based drug delivery carriers for cancer therapy

This brief summarizes different types of organic and inorganic nanomaterials for drug delivery in cancer therapy. It highlights that precisely designed nanomaterials will be the next-generation therapeutic agents for cancer treatment.

Saved in:
Bibliographic Details
Main Authors Feng, Tao (Author), Zhao, Yanli (Author)
Format Electronic eBook
LanguageEnglish
Published Abingdon, Oxon ; New York : Routledge, Taylor and Francis Group, 2017.
Singapore : Springer, 2017.
SeriesSpringerBriefs in applied sciences and technology. Nanotheranostics.
Subjects
Antineoplastic agents.
Drug carriers (Pharmacy)
elektronické knihy
electronic books
Online AccessFull text
ISBN9789811032998
9789811032974
ISSN2191-5318
Physical Description1 online resource (62 pages) : illustrations (some color)

Cover

Table of Contents:
  • Acknowledgements; Contents; About the Authors; 1 Current Status and Characteristics of Cancer; 1.1 Abnormal Metabolism; 1.2 Abnormal Vasculature; 1.3 Resistance to Anti-proliferative Growth Factors (GFs); 1.4 Unlimited Replicative Potential; 1.5 Immune System Activation and Inflammation; 1.6 Interstitial Pressure; References; 2 Clinical Anticancer Drugs for Cancer Treatment; 2.1 Antimetabolites; 2.2 Antimitotic Agents; 2.3 Alkylating Agents; 2.4 Antitumor Antibiotics; 2.5 Tyrosine Kinase Inhibitors (TKI); 2.6 Cyclin Dependent Kinase (CDK) Inhibitors.
  • 2.7 Poly(ADP-Ribose) Polymerase (PARP) Inhibitors2.8 Histone Deacetyltransferase Inhibitors (HDACi); 2.9 Mitogen-Activated Protein Kinase (MAPK) Kinase (MEK) Inhibitors; 2.10 Serine/Threonine-Protein Kinase B-Raf Inhibitors; 2.11 Mammalian Target of Rapamycin (MTOR) Inhibitors; 2.12 Phosphoinositide 3-Kinase (PI3K) Inhibitors; 2.13 Ribonucleotide Reductase (RNR) Inhibitors; 2.14 DNA Methyltransferase Inhibitors; 2.15 Retinoids; 2.16 Monoclonal Antibodies (MAbs); 2.17 Combination Therapy; References; 3 Nanomaterial-Based Drug Delivery Carriers for Cancer Therapy; 3.1 Introduction.
  • 3.2 Organic Nanomaterials3.2.1 FDA-Approved Liposomes; 3.2.2 Polymer-Based Nanoparticles; 3.2.3 Supramolecular Nanosystems; 3.2.4 Others; 3.3 Inorganic Nanomaterials; 3.3.1 Quantum Dots; 3.3.2 Gold Nanomaterials; 3.3.2.1 Gold Nanoparticles; 3.3.2.2 Gold Nanorods; 3.3.3 Mesoporous Silica Nanoparticles; 3.3.4 Carbon Nanomaterials; 3.3.4.1 Carbon Nanotubes; 3.3.4.2 Graphene; 3.3.4.3 Carbon Dots; 3.3.5 Upconversion Nanoparticles; 3.3.6 Two-Dimensional Nanomaterials; 3.3.7 Others; 3.4 Organic-Inorganic Hybrid Nanomaterials; References; Conclusions.

Similar Items